• Publications
  • Influence
The allometric approach for interspecies scaling of pharmacokinetic parameters.
A long standing problem in pharmacokinetics and toxicology is the extrapolation and correlation between results obtained in different animal species and man. Animal data may be scaled-up to predictExpand
  • 57
  • 3
High-performance liquid chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine.
A selective, accurate, precise and reproducible high-performance liquid chromatographic assay was developed for the quantitation of irbesartan, an angiotensin II antagonist, in human plasma and urineExpand
  • 46
  • 2
The effects of age and gender on the pharmacokinetics of irbesartan.
AIMS Single dose pharmacokinetics and safety of irbesartan, an angiotensin II receptor antagonist, were evaluated in healthy young and elderly male and female subjects. METHODS Irbesartan wasExpand
  • 51
  • 2
  • PDF
Oral Bioavailability and Disposition Characteristics of Irbesartan, an Angiotensin Antagonist, in Healthy Volunteers
Absolute oral bioavailability and disposition characteristics of irbesartan, an angiotensin II receptor antagonist, were investigated in 18 healthy young male volunteers. Subjects received [14C]Expand
  • 47
  • 2
Pharmacokinetics of Irbesartan Are Not Altered in Special Populations
Studies were conducted to determine whether pharmacokinetics of irbesartan (IRBE), a potent, long-acting angiotensin (AT)-II receptor antagonist selective for AT-II type 1 receptor subtype, areExpand
  • 18
  • 2
Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist.
BMS-214778 is a novel melatonin receptor agonist that may be a useful treatment for sleep disorders that result from disruption of circadian rhythms. Pharmacokinetic studies following intravenous andExpand
  • 43
  • 1
Drug Interactions with Irbesartan
AbstractIrbesartan is an angiotensin II receptor antagonist indicated for the treatment of patients with hypertension. Although irbesartan does not require biotransformation for its pharmacologicalExpand
  • 31
  • 1
An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.
OBJECTIVES This study evaluated flexible-dose pharmacokinetics, safety, and effectiveness of aripiprazole in children and adolescents with conduct disorder (CD). METHODS This open-label, 15-day,Expand
  • 37
  • 1
Review of electrolyte pharmacokinetics.
  • 3
  • 1
Validation and application of a sensitive assay for butorphanol in human plasma by high-performance liquid chromatography with tandem mass spectrometry detection.
A sensitive and convenient high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the opioid receptor agonist-antagonist butorphanol in human plasma is described.Expand
  • 5
  • 1